Our recent animal study with semaglutide confirmed the lack of GLP-1R expression in the liver, and indicated the mechanism for improving NAFLD/NASH to be indirect, via reduced inflammation (111). Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.